retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ retatrutide triple agonist glp-1 gip
Pay in 4 interest-free payments of $5.76 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15




01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)





















